Is ESA Loading Beneficial?
In this video blog, Jeffrey Berns, MD, from the University of Pennsylvania School of Medicine, discusses the value of ESA loading in hospitalized patients. Does it cause harm or benefit?
Video Rating: 0 / 5
Cardiovascular Risk with Erythropoietic Agents (Jan. 2007)
FDA is warning health care professionals that patients treated with erythropoietic agents may have an increased risk of cardiovascular complications if the dosing recommendations in the labeling are exceeded. These agents are used to stimulate the production of red blood cells in patients with severe anemia, and they are sold under the brand names Procrit, Epogen and Aranesp. FDA's advisory follows a recent study in the New England Journal of Medicine. In this study, anemic patients with chronic kidney disease were randomized to be dosed with Procrit to either a higher average target hemoglobin level (13.5 g/dL) or a lower level (11.3 g/dL). The patients being treated to the higher level experienced more cardiovascular complications than those being treated to the lower level. These complications included myocardial infarction, hospitalization for congestive heart failure, stroke and death. The labeling for Procrit, Epogen and Aranesp already recommends treating patients to achieve blood hemoglobin levels no higher than 12 g/dL. To reduce the risk of serious complications with these drugs, FDA's advisory says to be sure to follow the labeling recommendations, and maintain a hemoglobin range between 10 and 12 g/dL. In addition, after adjusting the dose of one of these agents, FDA recommends measuring the patient's hemoglobin twice a week for 2 to 6 weeks to ensure that hemoglobin levels have stabilized. Decrease the dose if the hemoglobin increase exceeds 1g/dL in any 2 ...
Video Rating: 5 / 5
Related Posts:
Orignal From: Is ESA Loading Beneficial?
No comments:
Post a Comment